CJC-1295 Acetate has garnered significant attention in the realm of peptide research due to its intriguing mechanism of action. This synthetic peptide analog of growth hormone-releasing hormone (GHRH) has piqued the interest of scientists and researchers alike for its potential to stimulate growth hormone secretion. In this comprehensive exploration, we'll delve into the intricate workings of CJC-1295 Acetate, uncovering its binding process, role in sustained growth hormone release, and the activation of crucial cellular pathways.
Product Code: BM-2-4-007
English Name: CJC-1295 Acetate
CAS No.: 863288-34-0
Molecular formula: C152H252N44O42
Molecular weight: 3367.89688
EINECS No.: 206-141-6
HS code: /
Analysis items: HPLC>99.0%, LC-MS
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand, Canada, etc.
Manufacturer: BLOOM TECH Changzhou Factory
Technology service: R&D Dept.-3
We provide CJC-1295 Acetate CAS 863288-34-0, please refer to the following website for detailed specifications and product information.
Product: https://www.bloomtechz.com/synthetic-chemical/peptide/cjc-1295-acetate-cas-863288-34-0.html
How does CJC-1295 Acetate bind to GHRH receptors?
The binding process of CJC-1295 Acetate to GHRH receptors is a fascinating dance of molecular recognition and interaction. This peptide's structure has been meticulously engineered to mimic the natural GHRH, allowing it to dock seamlessly with the receptors found on the surface of somatotroph cells in the anterior pituitary gland.
When CJC-1295 Acetate approaches the GHRH receptor, it initiates a series of conformational changes. The peptide's amino acid sequence aligns with specific binding sites on the receptor, forming a lock-and-key fit. This precise alignment triggers a cascade of intracellular events, setting the stage for the peptide's physiological effects.
The binding affinity of CJC-1295 Acetate to GHRH receptors is notably high, surpassing that of the native GHRH. This enhanced affinity is attributed to the peptide's modified structure, which includes strategic substitutions and additions that optimize its interaction with the receptor. The result is a more stable and longer-lasting bond, which contributes to the peptide's extended half-life and prolonged effects.
One of the key features that sets CJC-1295 Acetate apart is its incorporation of Drug Affinity Complex (DAC) technology. This innovative approach involves the addition of a lysine moiety, which allows the peptide to bind to albumin in the bloodstream. This albumin binding significantly extends the peptide's circulation time, effectively increasing its bioavailability and duration of action.
The binding process is not a static event but a dynamic interaction. As CJC-1295 Acetate engages with the GHRH receptor, it induces subtle changes in the receptor's conformation. These changes propagate through the receptor structure, ultimately leading to the activation of intracellular signaling pathways. This molecular choreography sets the stage for the peptide's downstream effects, including the stimulation of growth hormone synthesis and release.
It's worth noting that the binding of CJC-1295 Acetate to GHRH receptors is reversible. This reversibility is crucial for maintaining physiological balance and preventing overstimulation of the growth hormone axis. Once the peptide dissociates from the receptor, it can be cleared from the system or potentially rebind to other available receptors, depending on its concentration and the prevailing physiological conditions.
The specificity of CJC-1295 Acetate's binding is another critical aspect of its mechanism. While it primarily targets GHRH receptors, research has shown that it may also have some affinity for other related receptors in the secretin receptor family. This broader receptor interaction profile may contribute to some of the peptide's observed effects beyond growth hormone stimulation, though these interactions are generally less pronounced than its primary action on GHRH receptors.
Understanding the intricacies of CJC-1295 Acetate's binding process is crucial for appreciating its overall mechanism of action. This knowledge not only illuminates the peptide's immediate effects but also provides insights into its potential long-term impacts on growth hormone regulation and related physiological processes.
|
|
|
CJC-1295 Acetate's role in sustained GH secretion
Core Mechanism of Action
CJC-1295 Acetate achieves sustained growth hormone (GH) secretion by combining growth hormone-releasing hormone (GHRH) activity with Drug Affinity Complex (DAC) technology. This enables reversible albumin binding in circulation, creating a reservoir effect that prolongs peptide activity. Unlike short-acting GHRH analogs, it maintains stable plasma levels, providing continuous stimulation of pituitary somatotroph cells.
Physiological GH Release Pattern
The peptide mimics natural pulsatile GH secretion by avoiding sharp hormonal spikes. This steady release aligns with the body's circadian rhythm, supporting optimal tissue repair, metabolism, and anabolic processes. Such a profile reduces risks of side effects like fluid retention or insulin resistance linked to abrupt GH surges.
Enhanced Cellular Sensitivity
Prolonged exposure to CJC-1295 Acetate upregulates GHRH receptor expression and optimizes intracellular signaling in somatotroph cells. This heightened sensitivity amplifies the pituitary's response to endogenous GH-releasing signals, sustaining hormone production without overwhelming natural regulatory systems.
Modulation of Somatostatin Interactions
CJC-1295 Acetate may indirectly suppress somatostatin's inhibitory effects on GH secretion. By balancing the GHRH-somatostatin axis, it extends the duration of GH release while preserving hypothalamic-pituitary feedback mechanisms to prevent excessive hormone levels.
Stable IGF-1 Production
Sustained GH secretion drives consistent insulin-like growth factor 1 (IGF-1) synthesis in the liver. This stability enhances tissue repair, lipolysis, and muscle growth while minimizing fluctuations that could disrupt metabolic homeostasis.
Safety and Physiological Compatibility
The peptide operates within the body's natural regulatory framework. Its albumin-bound reservoir system ensures gradual release, avoiding supraphysiological GH concentrations. This self-limiting mechanism reduces risks of acromegaly-like symptoms or hormonal imbalance.
Pharmacokinetic Advantages
DAC technology extends CJC-1295 Acetate's half-life to 6–8 days, allowing less frequent dosing (2–3 times weekly). This contrasts with daily-administered peptides, improving compliance and reducing injection-related stress in clinical settings.
Therapeutic Implications
Metabolic Health: Steady GH/IGF-1 levels support fat oxidation and glucose regulation.
Anti-Aging Research: Mimicking youthful GH pulsatility may counteract age-related declines in tissue repair.
Musculoskeletal Recovery: Enhanced protein synthesis aids injury rehabilitation and muscle preservation.
Clinical Considerations
While promoting sustained GH release, CJC-1295 Acetate preserves circadian rhythm alignment. Its effects are dose-dependent, with studies showing linear increases in IGF-1 levels up to 60–90 μg/kg doses. Long-term safety data remain under investigation, particularly regarding prolonged receptor activation.
In summary, CJC-1295 Acetate's role in sustained GH secretion represents a significant advancement in peptide-based approaches to growth hormone modulation. By promoting a more physiological pattern of GH release, this peptide offers potential advantages in terms of efficacy, side effect profile, and dosing convenience. As research in this area continues, our understanding of the long-term implications of sustained GH secretion induced by CJC-1295 Acetate will undoubtedly expand, potentially opening new avenues for its application in various fields of endocrinology and metabolic research.
|
|
|
Why does CJC-1295 Acetate activate cAMP pathways?
Receptor Binding and cAMP Induction: CJC-1295 Acetate binds to GHRH receptors on pituitary somatotroph cells, activating stimulatory G-proteins (Gs). This triggers adenylyl cyclase to convert ATP into cyclic AMP (cAMP), elevating intracellular cAMP levels-a critical second messenger for GH secretion.
Downstream Signaling Cascade: Increased cAMP activates protein kinase A (PKA), which phosphorylates transcription factors like CREB. These regulate genes involved in GH synthesis and release, ensuring sustained hormone production rather than transient spikes.
Sustained Pathway Activation: Unlike natural GHRH, CJC-1295 Acetate's prolonged half-life (via DAC technology) maintains cAMP elevation over days. Continuous receptor stimulation supports stable GH output, mimicking physiological pulsatility.
Synergistic Effects with Other Secretagogues: CJC-1295 Acetate's cAMP-driven mechanism complements GH-releasing peptides (GHRPs) that act via calcium-dependent pathways. Combined use may amplify GH release through multi-pathway activation.
Cellular Growth and Survival: cAMP promotes somatotroph cell proliferation and viability, potentially expanding the pituitary's GH-producing capacity over time. This may enhance long-term efficacy in GH-deficient states.
Beyond GH: Systemic cAMP Effects: The peptide's cAMP modulation influences other pituitary hormones (e.g., prolactin, ACTH) and broader processes like metabolism and tissue repair, underscoring its systemic impact.
Cross-Talk with Other Pathways: While cAMP is primary, CJC-1295 Acetate may also engage MAPK and PI3K/Akt pathways, contributing to its anabolic and anti-apoptotic effects-an area of active research.
Therapeutic Potential: Targeting cAMP pathways could benefit metabolic disorders and age-related GH decline. However, precise dosing is crucial to avoid disrupting hormonal equilibrium.
In conclusion, the activation of cAMP pathways by CJC-1295 Acetate is a fundamental aspect of its mechanism of action. This process not only drives the peptide's primary effect on growth hormone secretion but also contributes to a broader range of physiological responses. As our understanding of these signaling cascades continues to evolve, it may open new avenues for the application of CJC-1295 Acetate and related peptides in various fields of biomedical research and potential therapeutic interventions.
Conclusion
In summary, CJC-1295 Acetate's mechanism of action is a multifaceted process that involves precise receptor binding, sustained growth hormone secretion, and activation of crucial cellular pathways. Its ability to bind effectively to GHRH receptors, coupled with its unique pharmacokinetic profile, allows for a prolonged stimulation of growth hormone release. The activation of cAMP pathways further amplifies its effects, influencing not only growth hormone production but also broader aspects of cellular function.
The intricate interplay between these mechanisms underscores the complexity of CJC-1295 Acetate's actions and highlights its potential significance in various research contexts. As we continue to unravel the nuances of its mechanism, we may uncover new applications and insights into growth hormone regulation and related physiological processes.
For those in the pharmaceutical industry seeking high-quality peptides for research purposes, or for professionals in the specialty chemicals sector looking for advanced compounds, Shaanxi BLOOM TECH Co., Ltd. offers a range of products that meet stringent quality standards. With our state-of-the-art GMP-certified production facilities and expertise in various chemical reactions and purification techniques, we are well-equipped to meet your specific needs. To learn more about our CJC-1295 Acetate and other chemical products, please don't hesitate to reach out to us at Sales@bloomtechz.com. Our team is ready to assist you with your inquiries and provide tailored solutions for your research or industrial applications.
References
Teichman, S. L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.
Alba, M., et al. (2006). Once-weekly administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.
Jetté, L., et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-3058.